Editas Medicine, Inc.
Company Stats
- Market Cap
- $394.7M
- as of Sep 30, 2026
- Shares Outstanding
- 153.6M
- Free Float
- 95.7%
Income Statement
- Revenue
- $40.5M
- Operating Income
- -$160.0M
- Net Income
- -$160.1M
- EBITDA
- -$154.7M
- Non-cash Impairment
- $3.8M
- Revenue Growth, 3Y
- 27.1%
- FCF Margin, 3Y Avg
- -420.9%
- FCF Margin, Worst Year
- -678.1%
Cash Flow
- Free Cash Flow
- -$165.8M
- FCF Yield
- -42.0%
- Owner FCF Yield
- -44.6%
Balance Sheet
- Cash & Equivalents
- $146.6M
Returns & Capital
- SBC, 3Y Avg
- $17.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $40.5M | -$165.8M | -409.3% |
| FY2024 | $32.3M | -$219.1M | -678.1% |
| FY2023 | $78.1M | -$136.9M | -175.2% |
| FY2022 | $19.7M | -$181.5M | -920.6% |
| FY2021 | $25.5M | -$171.8M | -672.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back